在芬兰 (FinTofUC) 治疗性结肠炎的托法西替尼实践经验:一项回顾性非干预性多中心患者病历数据研究
Pauliina Molander1, Mikko Kosunen2, Heli Eronen3
1Abdominal Center, Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Scandinavian journal of gastroenterology
|December 29, 2023
概括
在现实芬兰环境中,托法西提尼布在一年内在三分之一的性结肠炎患者中有效诱导无类固醇缓解. 大多数患者在早期实现缓解后,长期保持缓解,这表明持续的治疗效益.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD),具有显著的未满足需求.
- 托法西提尼布是一种Janus激酶抑制剂,为中度至重度UC提供了治疗选择.
- 现实世界的数据对于了解不同患者群体的治疗有效性至关重要.
研究的目的:
- 评估托法西提尼布在现实世界芬兰性结肠炎患者队列中的有效性.
- 描述接受托法西提尼布治疗UC的患者群体.
- 评估一年内临床缓解和无类固醇缓解率.
主要方法:
- 这是一项回顾性,非干预性,多中心研究,使用来自芬兰23个IBD中心的患者病历数据.
- 包括252名性结肠炎患者,分析人口统计和临床数据.
- 评估临床反应,临床缓解,无类固醇缓解,以及停止,切除或住院治疗的时间.
主要成果:
- 托法西提尼布在1年内分别在33%,34%和31%的患者中实现了临床反应,临床缓解和无类固醇临床缓解.
- 在16周pMayo缓解的患者中,64%的患者在一年内保持缓解.
- 在研究期间,观察到住院病例 (n=24) 和小肠切除术 (<5) 的低率.
结论:
- 托法西提尼布在实现无类固醇临床缓解方面表现出有效性,在大约三分之一的生物经验UC患者中,在一年内实现了缓解.
- 在大多数在16周内实现缓解的患者中,观察到持续缓解.
- 这些发现与之前的现实研究一致,支持托法西提尼布在UC管理中的作用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128


